Nifty
Sensex
:
:
24219.05
77369.11
-32.95 (-0.14%)
-171.72 (-0.22%)

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 500087 | NSE: CIPLA

1437.90
24-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1428
  •  1442.3
  •  1410.3
  •  1432.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1220646
  •  1745178416.9
  •  1673
  •  1165.7

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,15,926.93
  • 34.39
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,14,877.48
  • 0.91%
  • 3.30

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.21%
  • 0.46%
  • 13.73%
  • FII
  • DII
  • Others
  • 20.2%
  • 32.60%
  • 3.80%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.94
  • 5.29
  • 3.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.04
  • 5.45
  • -1.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.39
  • 8.97
  • -1.94

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.47
  • 29.07
  • 27.50

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.64
  • 3.89
  • 3.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.48
  • 16.02
  • 15.92

Earnings Forecasts:

(Updated: 22-08-2026)
Description
2026
2027
2028
2029
Adj EPS
53
-4
11.03
52.25
P/E Ratio
27.13
-359.48
130.36
27.52
Revenue
27.81
22.6
20.3
28380.5
EBITDA
31001.5
34600.6
38038.4
5989.88
Net Income
6098.22
7410.28
8270.78
4227.31
ROA
4181.95
5165.4
5791.08
10.56
P/B Ratio
-0.15
-0.12
-0.10
3.38
ROE
3.12
2.82
2.56
12.87
FCFF
11.58
12.89
13.13
3000.69
FCFF Yield
2596.32
3274.54
6420.09
2.74
Net Debt
2.37
2.99
5.87
-10165.5
BVPS
-9753.23
-11869.7
-14772.2
424.98

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
7,119.28
6,957.47
2.33%
6,541.20
6,729.69
-2.80%
7,074.48
7,072.97
0.02%
7,589.44
7,051.02
7.64%
Expenses
5,926.98
5,179.33
14.44%
5,544.23
5,192.10
6.78%
5,819.42
5,084.05
14.46%
5,694.69
5,165.43
10.25%
EBITDA
1,192.30
1,778.14
-32.95%
996.97
1,537.59
-35.16%
1,255.06
1,988.92
-36.90%
1,894.75
1,885.59
0.49%
EBIDTM
16.75%
25.56%
15.24%
22.85%
17.74%
28.12%
24.97%
26.74%
Other Income
210.90
258.56
-18.43%
148.16
289.46
-48.82%
206.34
221.61
-6.89%
268.95
190.61
41.10%
Interest
17.03
14.05
21.21%
13.13
14.02
-6.35%
14.03
14.64
-4.17%
13.18
15.40
-14.42%
Depreciation
304.24
252.72
20.39%
424.94
308.73
37.64%
278.35
279.80
-0.52%
296.99
271.74
9.29%
PBT
1,081.93
1,769.93
-38.87%
707.06
1,504.30
-53.00%
893.11
1,916.09
-53.39%
1,853.53
1,789.06
3.60%
Tax
294.83
477.88
-38.30%
156.95
279.28
-43.80%
218.55
332.37
-34.24%
500.46
483.04
3.61%
PAT
787.10
1,292.05
-39.08%
550.11
1,225.02
-55.09%
674.56
1,583.72
-57.41%
1,353.07
1,306.02
3.60%
PATM
11.06%
18.57%
8.41%
18.20%
9.54%
22.39%
17.83%
18.52%
EPS
9.77
16.06
-39.17%
6.87
15.13
-54.59%
8.37
19.45
-56.97%
16.73
16.13
3.72%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
28,324.40
28,162.59
27,547.62
25,774.09
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
Net Sales Growth
1.85%
2.23%
6.88%
13.28%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
 
Cost Of Goods Sold
10,045.58
9,549.11
8,928.99
8,819.57
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
Gross Profit
18,278.82
18,613.48
18,618.63
16,954.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
GP Margin
64.53%
66.09%
67.59%
65.78%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
Total Expenditure
22,985.32
22,279.69
20,424.78
19,483.04
17,762.83
17,251.38
14,910.94
13,951.18
13,265.10
12,329.33
11,918.50
Power & Fuel Cost
-
416.79
397.18
364.84
353.61
331.03
308.26
327.43
335.11
298.82
251.73
% Of Sales
-
1.48%
1.44%
1.42%
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
Employee Cost
-
5,366.33
4,832.83
4,310.04
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
% Of Sales
-
19.05%
17.54%
16.72%
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
Manufacturing Exp.
-
2,174.08
1,894.12
1,779.35
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
% Of Sales
-
7.72%
6.88%
6.90%
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
General & Admin Exp.
-
1,868.24
1,772.59
1,673.94
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
% Of Sales
-
6.63%
6.43%
6.49%
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
Selling & Distn. Exp.
-
1,934.24
1,834.86
1,724.97
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
% Of Sales
-
6.87%
6.66%
6.69%
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
Miscellaneous Exp.
-
970.90
764.21
810.33
619.43
565.55
508.00
692.12
626.24
595.99
1,009.21
% Of Sales
-
3.45%
2.77%
3.14%
2.72%
2.60%
2.65%
4.04%
3.83%
3.93%
4.48%
EBITDA
5,339.08
5,882.90
7,122.84
6,291.05
4,990.29
4,511.96
4,248.65
3,180.81
3,097.31
2,826.38
2,475.79
EBITDA Margin
18.85%
20.89%
25.86%
24.41%
21.93%
20.73%
22.18%
18.57%
18.93%
18.65%
17.20%
Other Income
834.35
882.01
866.93
746.57
512.13
321.73
269.77
369.38
476.57
357.65
228.69
Interest
57.37
54.39
62.01
89.88
109.54
106.35
160.70
197.36
168.43
114.23
159.38
Depreciation
1,304.52
1,210.98
1,106.95
1,051.02
1,172.11
1,051.95
1,067.66
1,174.65
1,326.31
1,322.82
1,322.93
PBT
4,535.63
5,499.54
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
Tax
1,170.79
1,353.84
1,529.76
1,546.59
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
Tax Rate
25.81%
25.92%
22.43%
27.12%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
PAT
3,364.84
3,887.28
5,294.37
4,123.14
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
PAT before Minority Interest
3,379.82
3,869.79
5,291.05
4,155.31
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
Minority Interest
14.98
17.49
3.32
-32.17
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
PAT Margin
11.88%
13.80%
19.22%
16.00%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
PAT Growth
-37.77%
-26.58%
28.41%
47.02%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
 
EPS
41.78
48.27
65.74
51.19
34.82
31.41
30.02
19.79
19.18
17.55
12.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
34,431.95
31,193.45
26,706.43
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
Share Capital
161.56
161.52
161.47
161.43
161.36
161.29
161.25
161.14
161.02
160.90
Total Reserves
34,207.89
30,917.81
26,458.42
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
Non-Current Liabilities
61.13
-31.04
81.92
183.53
621.70
1,660.06
2,972.37
4,646.15
4,259.05
4,513.35
Secured Loans
0.00
0.00
0.00
332.46
376.20
355.32
304.74
47.70
0.00
0.00
Unsecured Loans
117.47
11.98
0.00
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
Long Term Provisions
157.56
148.69
129.26
102.16
100.22
116.17
133.27
121.41
137.92
140.52
Current Liabilities
7,013.59
5,483.96
5,245.77
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,373.70
Trade Payables
3,229.90
2,837.49
2,473.98
2,534.52
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,571.14
Other Current Liabilities
1,378.59
772.99
890.98
1,007.60
769.81
1,093.21
706.65
541.86
647.04
908.95
Short Term Borrowings
140.50
80.12
247.02
187.90
393.34
334.73
447.15
486.16
435.87
467.23
Short Term Provisions
2,264.60
1,793.36
1,633.79
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.38
Total Liabilities
41,594.96
36,742.17
32,130.02
28,930.34
26,651.95
24,836.79
23,422.79
23,761.91
22,672.90
20,868.94
Net Block
12,434.36
9,895.14
9,493.61
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,490.24
Gross Block
23,825.03
19,655.92
18,160.54
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,352.78
Accumulated Depreciation
11,343.39
9,707.76
8,573.36
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
Non Current Assets
17,447.93
13,453.65
12,688.61
11,731.79
11,924.75
11,627.69
11,716.61
11,335.28
11,858.80
12,064.31
Capital Work in Progress
2,042.22
1,566.27
1,152.72
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
Non Current Investment
543.99
639.54
642.21
572.52
355.63
423.68
454.50
428.35
156.63
135.62
Long Term Loans & Adv.
1,321.80
1,038.36
844.39
849.46
736.39
645.57
677.08
455.57
514.96
543.67
Other Non Current Assets
1,105.56
203.09
442.07
56.03
383.22
74.03
77.61
166.82
255.71
210.06
Current Assets
24,145.86
23,248.97
19,392.45
16,805.06
14,710.83
13,181.03
11,703.84
12,424.63
10,814.10
8,735.57
Current Investments
7,679.42
7,293.23
4,807.01
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
Inventories
6,596.72
5,642.11
5,237.95
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,485.28
Sundry Debtors
5,620.05
5,506.37
4,770.66
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,563.05
Cash & Bank
1,307.42
799.84
874.97
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
624.21
Other Current Assets
2,942.25
526.00
567.64
373.99
1,812.70
1,378.57
1,414.50
1,564.48
1,599.13
1,225.64
Short Term Loans & Adv.
2,367.55
3,481.42
3,134.22
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.47
Net Current Assets
17,132.27
17,765.01
14,146.68
11,771.79
9,797.96
8,589.89
7,310.70
8,653.12
6,981.88
5,361.87
Total Assets
41,593.79
36,702.62
32,081.06
28,536.85
26,635.58
24,808.72
23,420.45
23,759.91
22,672.90
20,799.88

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
3,940.02
5,004.98
4,133.91
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
PBT
5,223.63
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
Adjustment
527.81
517.74
640.77
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
Changes in Working Capital
-225.22
-665.47
-806.10
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
Cash after chg. in Working capital
5,526.22
6,673.08
5,731.39
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,586.20
-1,668.10
-1,597.48
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,326.13
-3,691.14
-2,988.03
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
Net Fixed Assets
-2,339.05
-626.50
-373.49
-600.42
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
Net Investments
-265.34
-3,557.23
-1,884.41
-935.67
-1,247.85
-2,536.08
-1,374.56
-1,178.21
-351.09
-30.11
Others
278.26
492.59
-730.13
-852.42
-302.10
586.38
1,929.01
-317.31
6.92
-391.06
Cash from Financing Activity
-1,233.65
-1,292.79
-1,200.43
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
Net Cash Inflow / Outflow
380.24
21.05
-54.55
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
Opening Cash & Equivalents
542.65
512.34
561.33
658.11
790.43
649.13
508.36
853.47
610.35
858.15
Closing Cash & Equivalent
1,015.39
542.65
512.34
561.33
658.11
790.43
742.38
508.36
853.46
610.35

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
425.47
384.84
329.72
289.24
257.78
226.73
194.85
185.62
175.92
155.15
ROA
9.88%
15.36%
13.59%
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
ROE
11.83%
18.34%
16.63%
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
ROCE
16.00%
23.64%
22.77%
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
Fixed Asset Turnover
1.79
1.96
2.00
1.81
1.82
1.85
1.89
1.79
1.25
1.36
Receivable days
52.05
50.64
45.49
44.13
42.19
47.44
54.10
55.36
68.17
61.60
Inventory Days
57.25
53.61
53.56
61.98
61.53
58.49
56.12
61.13
90.71
91.41
Payable days
115.96
108.56
103.64
111.52
98.28
107.95
128.84
59.02
57.37
46.96
Cash Conversion Cycle
-6.65
-4.31
-4.58
-5.41
5.44
-2.02
-18.63
57.47
101.50
106.05
Total Debt/Equity
0.01
0.00
0.01
0.02
0.04
0.10
0.18
0.29
0.29
0.33
Interest Cover
97.04
111.00
64.44
37.87
33.85
21.47
12.04
13.34
15.61
8.67

News Update:


  • Cipla's arm gets EIR for manufacturing facility in USA
    4th Aug 2026, 11:59 AM

    Earlier, InvaGen had received two inspectional observations in Form 483 from USFDA for said manufacturing facility

    Read More
  • Cipla gets USFDA’s approval for Generic Advair Diskus
    28th Jul 2026, 10:19 AM

    The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

    Read More
  • Cipla - Quarterly Results
    24th Jul 2026, 00:00 AM

    Read More
  • Cipla reports 39% fall in Q1 consolidated net profit
    23rd Jul 2026, 14:11 PM

    Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

    Read More
  • USFDA completes cGMP Inspection at Cipla’s arm’s New York facility
    18th Jul 2026, 17:34 PM

    On conclusion of the inspection, the company has received one inspectional observation in Form 483

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.